Management

Raymond J. Tesi, MD,CEO/CMO:  Dr. Tesi has been our President, Chief Executive Officer and acting Chief Medical Officer since the formation of the Company in September 2015.  From November 2011 until May 2015, Dr. Tesi was CEO, President and Acting Chief Medical Officer of FPRT Bio Inc., a development stage biotech formed to develop XPro1595 for the treatment of neurodegenerative disease and other inflammatory diseases.  From November 2010 to October 2011, Dr. Tesi was Chief Medical Officer of Adienne SRL, an emerging biotech in Bergamo, Italy focused on products to treat patients with hematologic malignancy.  From June 2007 to September 2010, Dr. Tesi was founder, CEO and President of Coronado Biosciences. Dr. Tesi received his MD degree from Washington University School of Medicine in 1982. Dr. Tesi has been a licensed physician since 1982 and Fellow of the American College of Surgery since 1991.  Dr. Tesi’s significant experience with our licensed technology and his experience as a transplant surgeon, entrepreneur, investor and director of start-up biopharmaceutical companies were instrumental in his selection as a member of the board of directors.

David J. Moss, CFO:  David Moss has been CFO since its formation in September 2015. Mr. Moss has founded, funded and taken public various companies in a variety of industries since 1995, most recently Tonix Pharmaceuticals (NASDAQ: TNXP). Mr. Moss was a founding investor in Reliant Service Group LLC which recently sold in 2015 to leading private equity firm. Mr. Moss previously served as Managing Director, Corporate Finance for a New York based securities firm where he advised companies on corporate strategy, financings and business development. He also served as Managing Partner at a Seattle based venture capital firm. Mr. Moss holds an MBA from Rice University and a BA in Economics from the University of California, San Diego. Mr. Moss was selected as a Director due to his extensive entrepreneurial background and his substantial financial and accounting experience.

Professor Mark Lowdell, PhD. CSO/CMO: Prof. Lowdell has been a Chief Scientific Officer and Chief Manufacturing Officer since its formation in September 2015.   Prof. Lowdell is Professor of Cell and Tissue Therapy at University College London where he has led a translational immunotherapy group since 1994.  Since February 2009, Prof. Lowdell has also been Director of Cellular Therapy at the Royal Free London NHS Foundation Trust.   He received his PhD in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.  Prof. Lowdell’s education and significant academic and clinical experience with cellular therapies were instrumental in his selection as Chair of the SAB.

Got a question?
858 964 3720
Email Us
dmoss@inmunebio.com
Opening Hours
M - F 8am to 5pm PST